Evidence map›Paper›PMID 24633313›Full record

Trial reportHuman vaccines & immunotherapeutics2014

Immune responses induced by T-cell vaccination in patients with rheumatoid arthritis.

Irina Ivanova, Galina Seledtsova, Sergey Mamaev, Alexey Shishkov, Viktor Seledtsov

Open access · hybridAbstract readClinical Trial
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Irina IvanovaThe Laboratory of Cellular Biotechnologies; State Research Institute for Clinical Immunology; Novosibirsk, Russia.
Galina SeledtsovaThe Laboratory of Cellular Biotechnologies; State Research Institute for Clinical Immunology; Novosibirsk, Russia.
Sergey MamaevFederal State-funded Health Care Institution Clinical Hospital No 85; Russian Federal Medical and Biological Agency; Moscow, Russia.
Alexey ShishkovThe Laboratory of Cellular Biotechnologies; State Research Institute for Clinical Immunology; Novosibirsk, Russia.
Viktor SeledtsovResearch and Implementation Centre for Medical Biotechnologies; Immanuel Kant Baltic Federal University; Kaliningrad, Russia.
Research Institute of Fundamental and Clinical Immunology · RUFederal Agency for Health and Social Development · RUImmanuel Kant Baltic Federal University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with rheumatoid arthritis (RA) were treated with a cellular vaccine, which consisted of autologous collagen-reactive T-cells. This study showed that antigen-specific proliferative activity of the peripheral blood mononuclear cells was significantly downregulated after T-cell vaccination in RA patients. T-cell vaccination resulted in a statistically significant decrease in plasma IFNγ levels and a concomitant increase in IL-4 levels in treated patients. Accordingly, following T-cell vaccination the number of IFNγ-producing CD4(+) and CD8(+) T-cells was decreased by 1.6-1.8-fold, which was paralleled by 1.7-fold increases in IL-4-producing CD4(+) T-cells. In addition, the present study showed 5-7-fold increase in the CD8(+)CD45RO(+)CD62L(-) effector memory T-cells and central memory T-cells (both CD4(+) CD45RO(+)CD62L(+) T-cells and CD8(+)CD45RO(+)CD62L(+) T-cells) in RA patients, as compared with healthy individuals. We observed significant reduction in CD4(+) and CD8(+) central memory T-cells, as well as reduction in CD8(+) effector memory T-cells in vaccinated patients in the course of the treatment. We also demonstrated that CD4(+)CD25(+)FoxP3(+) regulatory T-cell levels were significantly up-regulated in the peripheral blood of RA patients following T-cell vaccination. However, CD4(+)CD25(-)FoxP3(+) Т-cell levels did not significantly change during the entire T-cell vaccination course. In conclusion, the T-cell immunotherapy regimen used resulted in the clinical improvement, which was achieved in 87% patients.

Indexed as

AdultArthritis, RheumatoidCells, CulturedFemaleHumansImmunity, CellularLeukocytes, MononuclearMaleMiddle AgedT-Lymphocytes, RegulatoryVaccinationclinical studyKeywords:T-cell vaccinesregulatory T-cellsrheumatoid arthritis

Identifiers

PMID24633313
PMCPMC4896593
OpenAlexW2069106953

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.